Peter A. Jones, PhD, DSc
Norris Comprehensive Cancer Center
University of Southern California
Los Angeles, California
Dr. Jones is internationally renowned for his innovative studies on the molecular biology of cancer and of the basic mechanisms of DNA methylation. In 1980, he made a seminal discovery that the drug 5-azacytidine could induce profound changes in gene expression at the same time as being a powerful inhibitor of DNA methylation. This discovery was the first to causally link DNA cytosine methylation, differentiation, and gene expression and played a large part in opening the now burgeoning field of epigenetics. The FDA has approved 5-azacytidine for use in the treatment of the myelodysplastic syndromes, which are disorders of the stem cells in bone marrow.
DNA Methylation Changes in Human Cancer
Cancer Center Director Nicholas Vogelzang, MD, and Peter A. Jones, PhD